<DOC>
	<DOCNO>NCT00475813</DOCNO>
	<brief_summary>Study compare efficacy safety FLUTIFORM® Seretide® treatment mild moderate persistent asthma pediatric subject .</brief_summary>
	<brief_title>Study FLUTIFORM® VS Seretide® Paediatric Subjects With Asthma</brief_title>
	<detailed_description>This study involve 12 week treatment phase follow 6 month extension phase . During treatment phase subject receive FLUTIFORM® Seretide® . In extension phase subject receive FLUTIFORM® . Efficacy assess lung function test asthma symptom , sleep disturbance . Safety assess adverse event , vital sign , lab test ECGs .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male female patient 412 year age . Female patient must premenarche eligible . Known history mild moderate reversible asthma ≥ 6 month prior screen visit . Demonstrate FEV1 ≥60 % ≤80 % predict normal value ( Zapletal , 1977 ) screen phase follow appropriate withhold asthma medication ( applicable ) . No beta agonist use day screen . No use combination asthma therapy day screen . Inhaled corticosteroid allow day screen . Documented reversibility ≥ 15 % FEV1 screening phase . Demonstrate satisfactory technique use pressurize MDI spacer device . Willing able enter information electronic diary ( parental help acceptable young child ) attend study visit . Willing able substitute study medication pre study prescribe asthma medication duration study . Written inform parental consent obtain , possible informed assent patient . Lifethreatening asthma within past year . This category include patient history nearfatal asthma , hospitalization emergency visit asthma prior intubation asthma . History systemic ( injectable ) corticosteroid medication within 1 month Screening Visit . History leukotriene receptor antagonist use , e.g . montelukast , within past week . Current evidence history clinically significant disease abnormality include uncontrolled coronary artery disease , congestive heart failure , cardiac dysrhythmia . 'Clinically significant ' defined disease , opinion Investigator , would put patient risk study participation , would affect outcome study . An upper low respiratory infection within 4 week prior Screening Visit . Significant , nonreversible , active pulmonary disease ( e.g. , chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , bronchiectasis , tuberculosis ) . Known Human Immunodeficiency Virus ( HIV ) positive status . Current smoke history within 12 month prior Screening Visit . Current evidence history alcohol and/or substance abuse within 12 month prior Screening Visit . Patients take Bblocking agent , tricyclic antidepressant , monoamine oxidase inhibitor , astemizole ( Hismanal ) , quinidine type antiarrhythmic , potent CYP 3A4 inhibitor ketoconazole within past week . Current use medication effect bronchospasm and/or pulmonary function . Current evidence history hypersensitivity idiosyncratic reaction test medication component . Receipt investigational drug within 30 day Screening Visit ( 12 week oral injectable steroid ) . Current participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Paediatric subject asthma</keyword>
</DOC>